Literature DB >> 33742225

Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network.

Alessia Pepe1, Michele Rizzo2, Sara Galimberti3, Claudia Baratè3, Esther Natalie Oliva4, Francesco Arcioni5, Sergio Storti6, Stefania Renne7, Massimo Midiri8, Gennaro Restaino9, Vincenzo Positano10, Maurizio Mangione11, Antonella Meloni10.   

Abstract

We prospectively evaluated changes in cardiac and hepatic iron overload (IO) and in morpho-functional cardiac parameters and myocardial fibrosis by magnetic resonance imaging (MRI) in patients with low-risk and intermediate-1-risk myelodysplastic syndromes (MDS). Fifty patients enrolled in the Myocardial Iron Overload in MyElodysplastic Diseases (MIOMED) study were followed for 12 months. IO was quantified by the T2* technique and biventricular function parameters by cine images. Macroscopic myocardial fibrosis was detected by late gadolinium enhancement technique. Twenty-eight patients (71.89±8.46 years; 8 females) performed baseline and follow-up MRIs. Thirteen patients had baseline hepatic IO, with a higher frequency among transfusion-dependent patients. Out of the 15 patients with a baseline MRI liver iron concentration <3 mg/g/dw, two (non-chelated) developed hepatic IO. Thirteen (46.4%) patients had an abnormal T2* value in at least one myocardial segment. One patient without hepatic IO and non-transfused had baseline global T2* <20 ms. Among the 15 patients with no baseline myocardial IO (MIO), 2 worsened. There was a significant increase in both left and right ventricular end-diastolic volume indexes. Thirty-six percent of patients showed myocardial fibrosis correlating with aging. Two new occurrences were detected at the follow-up. In conclusion, by a more sensitive segmental approach, MIO is quite frequent in MDS patients and it can be present also in non-transfused patients and in absence of detectable hepatic iron. The incidence of cardiac and hepatic IO and of myocardial fibrosis and the increase in biventricular volumes after a 12-month interval suggest performing periodic MRI scans to better manage MDS patients.

Entities:  

Keywords:  Iron overload; Longitudinal studies; Magnetic resonance imaging; Myelodysplastic syndromes

Year:  2021        PMID: 33742225     DOI: 10.1007/s00277-021-04495-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  44 in total

1.  Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.

Authors:  Roger M Lyons; Billie J Marek; Carole Paley; Jason Esposito; Katie McNamara; Paul D Richards; Nicholas DiBella; Guillermo Garcia-Manero
Journal:  Leuk Res       Date:  2017-01-31       Impact factor: 3.156

2.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

Review 3.  Pathogenesis, etiology and epidemiology of myelodysplastic syndromes.

Authors:  C Aul; D T Bowen; Y Yoshida
Journal:  Haematologica       Date:  1998-01       Impact factor: 9.941

4.  Cause of death in patients with lower-risk myelodysplastic syndrome.

Authors:  Farshid Dayyani; Anthony P Conley; Sara S Strom; William Stevenson; Jorge E Cortes; Gautam Borthakur; Stefan Faderl; Susan O'Brien; Sherry Pierce; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

Review 5.  Balancing acts: molecular control of mammalian iron metabolism.

Authors:  Matthias W Hentze; Martina U Muckenthaler; Nancy C Andrews
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

Review 6.  Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.

Authors:  Stuart L Goldberg
Journal:  Leuk Res       Date:  2007-12       Impact factor: 3.156

7.  Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias.

Authors:  Anna Angela Di Tucci; Gildo Matta; Simona Deplano; Attilio Gabbas; Cristina Depau; Daniele Derudas; Giovanni Caocci; Annalisa Agus; Emanuele Angelucci
Journal:  Haematologica       Date:  2008-07-04       Impact factor: 9.941

8.  Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.

Authors:  Joseph Chacko; Dudley J Pennell; Mark A Tanner; Terry J Hamblin; Beatrix Wonke; Terry Levy; Peter W Thomas; Sally B Killick
Journal:  Br J Haematol       Date:  2007-07-04       Impact factor: 6.998

9.  Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.

Authors:  Emanuele Angelucci; Junmin Li; Peter Greenberg; Depei Wu; Ming Hou; Efreen Horacio Montano Figueroa; Maria Guadalupe Rodriguez; Xunwei Dong; Jagannath Ghosh; Miguel Izquierdo; Guillermo Garcia-Manero
Journal:  Ann Intern Med       Date:  2020-03-24       Impact factor: 25.391

Review 10.  Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2008-06-27       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.